Replies to post #405153 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Another incorrect statement...

new presentation contained less information about the P2b/3 results , instead of more.

The JP Morgan preso included MORE info... for one, the CDR-SB chart which clearly showed that treated patients reached a similar level of benefit 7 months earlier than lecanecrap, and with more advanced AD patients.

You apparently don't understand that the Odds Ratios indicate that the # of treated patients, who exceeded the improvement thresholds, were >3x (ADAS-Cog) and >4x (ADCS-ADL) compared with placebo.

That's some impressive results... where ALL ENDPOINTS WERE MET, and patients actually IMPROVED!

[WolfofMia]

Again not what was claimed from what IR told this individual.

But sure Bob!

What a waste of time LOL!

[WolfofMia]

In case you have forgotten, what a flat out lie or hopeful fool looks like!

I highlighted the LIE/hopeful theory!

Spoke with IR, just an update. Company still working on TLR. They consider CTAD presentation an "initial results" only, are aware of all the investor and analyst questions and intend to address them with the TLR. May get it done and released before the JPM HC. Company is "excited" by the results and wants to get them out. It will include some sub-grouping (no specifics asked or offered).

[Steady_T]

https://video.wixstatic.com/video/79bcf7_6566f1d485d2424eadf745c64a05ff7a/480p/mp4/file.mp4